

Kevin J Sampson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12057564/publications.pdf>

Version: 2024-02-01

34
papers

1,810
citations

304743

22
h-index

434195

31
g-index

34
all docs

34
docs citations

34
times ranked

2254
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20990-20995.	7.1	309
2	Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. Journal of General Physiology, 2013, 141, 61-72.	1.9	189
3	Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. British Journal of Pharmacology, 2006, 148, 16-24.	5.4	151
4	Autonomic Control of Cardiac Action Potentials. Circulation Research, 2005, 96, e25-34.	4.5	139
5	KCNE1 alters the voltage sensor movements necessary to open the KCNQ1 channel gate. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 22710-22715.	7.1	119
6	Unique Cardiac Purkinje Fiber Transient Outward Current I_2 -Subunit Composition. Circulation Research, 2013, 112, 1310-1322.	4.5	77
7	KCNE1 divides the voltage sensor movement in KCNQ1/KCNE1 channels into two steps. Nature Communications, 2014, 5, 3750.	12.8	76
8	Allosteric gating mechanism underlies the flexible gating of KCNQ1 potassium channels. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7103-7108.	7.1	74
9	Altered Na ⁺ Channels Promote Pause-Induced Spontaneous Diastolic Activity in Long QT Syndrome Type 3 Myocytes. Circulation Research, 2006, 99, 1225-1232.	4.5	63
10	Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation. Journal of the American College of Cardiology, 2016, 68, 1756-1764.	2.8	63
11	Loss-of-Function <i>ABCC8</i> Mutations in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2018, 11, e002087.	3.6	62
12	A Novel and Lethal De Novo LQT-3 Mutation in a Newborn with Distinct Molecular Pharmacology and Therapeutic Response. PLoS ONE, 2007, 2, e1258.	2.5	50
13	Cardiac Delayed Rectifier Potassium Channels in Health and Disease. Cardiac Electrophysiology Clinics, 2016, 8, 307-322.	1.7	50
14	Biophysical properties of slow potassium channels in human embryonic stem cell derived cardiomyocytes implicate subunit stoichiometry. Journal of Physiology, 2011, 589, 6093-6104.	2.9	41
15	A Novel LQT-3 Mutation Disrupts an Inactivation Gate Complex with Distinct Rate-Dependent Phenotypic Consequences. Channels, 2007, 1, 273-280.	2.8	34
16	Adrenergic regulation of a key cardiac potassium channel can contribute to atrial fibrillation: evidence from an I_{Ks} transgenic mouse. Journal of Physiology, 2008, 586, 627-637.	2.9	34
17	Characterization of KCNQ1 atrial fibrillation mutations reveals distinct dependence on KCNE1. Journal of General Physiology, 2012, 139, 135-144.	1.9	34
18	The Impact of Heterozygous <i>KCNK3</i> Mutations Associated With Pulmonary Arterial Hypertension on Channel Function and Pharmacological Recovery. Journal of the American Heart Association, 2017, 6, .	3.7	34

#	ARTICLE	IF	CITATIONS
19	Reengineering an Antiarrhythmic Drug Using Patient hiPSC Cardiomyocytes to Improve Therapeutic Potential and Reduce Toxicity. <i>Cell Stem Cell</i> , 2020, 27, 813-821.e6.	11.1	33
20	The cardiac I _{Ks} channel, complex indeed. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18751-18752.	7.1	32
21	An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval. <i>Drug Safety</i> , 2016, 39, 433-441.	3.2	30
22	Purkinje Cells as Sources of Arrhythmias in Long QT Syndrome Type 3. <i>Scientific Reports</i> , 2015, 5, 13287.	3.3	29
23	Perturbation of sodium channel structure by an inherited Long QT Syndrome mutation. <i>Nature Communications</i> , 2012, 3, 706.	12.8	23
24	Gating mechanisms underlying deactivation slowing by two KCNQ1 atrial fibrillation mutations. <i>Scientific Reports</i> , 2017, 7, 45911.	3.3	20
25	Molecular mechanisms of adrenergic stimulation in the heart. <i>Heart Rhythm</i> , 2010, 7, 1151-1153.	0.7	16
26	Modeling Tissue- and Mutation- Specific Electrophysiological Effects in the Long QT Syndrome: Role of the Purkinje Fiber. <i>PLoS ONE</i> , 2014, 9, e97720.	2.5	10
27	Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5384-5403.	6.4	8
28	Human iPSC-derived cardiomyocytes and pyridyl-phenyl mexiletine analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 46, 128162.	2.2	5
29	Novel Mechanism of Transient Outward Potassium Channel Current Regulation in the Heart. <i>Circulation Research</i> , 2015, 116, 1633-1635.	4.5	2
30	Location, location, regulation: a novel role for β -spectrin in the heart. <i>Journal of Clinical Investigation</i> , 2010, 120, 3434-3437.	8.2	2
31	Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. <i>Journal of Cell Biology</i> , 2013, 200, i3-i3.	5.2	1
32	Ion Channels as Targets for Drugs. , 2012, , 525-534.		0
33	K ⁺ Channelopathies (IKs, IKr, and Ito). , 2013, , 233-244.		0
34	Adrenergic Regulation and Heritable Arrhythmias: Key Roles of the Slowly Activating Heart I _{Ks} Potassium Channel. , 2011, , 451-460.		0